Becton Dickinson & Co BDX
Becton Dickinson & Co (NYSE: BDX) is a medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BD Alaris Infusion System | IV infusion | — | NA_NON_THERAPEUTIC |
| Medication Delivery Solutions (catheters, syringes) | vascular access / drug delivery | — | NA_NON_THERAPEUTIC |
| BD Interventional (Surgery, Peripheral Intervention, Urology) | surgical / vascular | — | NA_NON_THERAPEUTIC |
| BD BioPharma Systems (prefillable syringes) | pharma packaging | — | NA_NON_THERAPEUTIC |
Recent results and decisions
- Nov 5, 2026positive BD announced six-month interim results from the ARCH clinical study of BD Liverty TIPS Stent Graft, supporting the U.S. launch for portal hypertension care.
Announced the BD® Liverty™ TIPS Stent Graft U.S. launch, advancing portal hypertension care with a next‑generation interventional solution for patients with advanced liver disease, building on established clinical and physician experience in Europe and supported by six-month interim results from the
Filing - Nov 5, 2026positive BD announced positive nine-month results from the iliac cohort of the AGILITY clinical trial demonstrating high vessel patency and low reintervention rates.
Announced positive nine-month results from the iliac cohort of the AGILITY clinical trial of the BD® Revello™ Vascular Covered Stent, with data demonstrating high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms.
Filing - Nov 5, 2026started BD surpassed the first enrollment milestone in the STANCE clinical trial evaluating BD GalaFLEX LITE Scaffold in breast revision surgery.
Surpassed the first enrollment milestone in the STANCE clinical trial evaluating BD® GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture and malposition, the most frequent complication of implant-based breast surgery.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.